TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05871346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complementary feeding counseling
Description: Complementary Feeding Counseling to Improve Appropriate Complementary Feeding Practices and Reduce Child Undernutrition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complementary feeding counseling
Description: Complementary Feeding Counseling to Improve Appropriate Complementary Feeding Practices and Reduce Child Undernutrition
Study: NCT06466902

Intervention type: OTHER
Intervention: Quality assessment of D2 lymphadenectomy using the PhotoNode Score
Description: During the surgical procedure, a set of 5 high quality laparoscopic intraoperative images of the surgical field will be put on record. Photographs will be taken at the end of the lymphadenectomy phase, before the reconstructive phase begins.~Three surgeons will review the images. Quality of D2 lymphadenectomy will be assessed independently rating eight node stations (1, 5, 6, 7, 8a, 9, 11p and 12a), based upon the evaluation of the 5 images. Each node station will be given a score from 0 to 3, corresponding to a judgment of Unevaluable (0), Poor (1), Doubtful (2) or Excellent (3) lymphadenectomy respectively, in that specific node station.~A total score for each patient will be independently obtained from each reviewer ranging from a minimum of 7 (poor lymphadenectomy) to a maximum of 24 (excellent lymphadenectomy). The PNS for each patient will originate from the average score among the three reviewers.
Study: NCT04788433

Intervention type: DIAGNOSTIC_TEST
Intervention: glycomic analysis
Description: Analysis of glycans on plasma samples

Intervention type: DIAGNOSTIC_TEST
Intervention: glycomic analysis
Description: Analysis of glycans on plasma samples

Intervention type: DIAGNOSTIC_TEST
Intervention: glycomic analysis
Description: Analysis of glycans on plasma samples

Intervention type: DIAGNOSTIC_TEST
Intervention: glycomic analysis
Description: Analysis of glycans on plasma samples

Intervention type: DIAGNOSTIC_TEST
Intervention: glycomic analysis
Description: Analysis of glycans on plasma samples

Intervention type: OTHER
Intervention: Phone interview
Description: patients are followed up by phone up to 1 year

Intervention type: OTHER
Intervention: Phone interview
Description: patients are followed up by phone up to 1 year

Intervention type: OTHER
Intervention: Phone interview
Description: patients are followed up by phone up to 1 year

Intervention type: OTHER
Intervention: Phone interview
Description: patients are followed up by phone up to 1 year

Intervention type: OTHER
Intervention: Phone interview
Description: patients are followed up by phone up to 1 year
Study: NCT05705700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: High dose Dutasteride (3.5 mg daily) as add-on therapy at time of PSA progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: 1000 mg PO daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: 1000 mg PO daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: 1000 mg PO daily
Study: NCT04852432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula
Description: The heated air is administered at a rate of 2L/kg/min using an Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand). Inhalation oxygen concentration starts with 50%.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal prong
Description: Oxygen is administered via nasal prong
Study: NCT05903833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg Q6W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg QD
Study: NCT05723510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50mg
Description: Oral administration of one tablet of tegoprazan 50 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50mg
Description: Oral administration of one tablet of tegoprazan 50 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50mg
Description: Oral administration of one tablet of tegoprazan 50 mg once daily
Study: NCT05674344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo Temperature device
Description: Non-invasive temperature device
Study: NCT06137950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gel Interferon arm
Description: 0.2 ml gel interferon will be administered into vaginal using 1 ml syringe with measurement line. Patients will be trained how to fill the syringe and put into the vagina. Gel will be administered 2 times per day during the non menstruating day totally for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gel Interferon arm
Description: 0.2 ml gel interferon will be administered into vaginal using 1 ml syringe with measurement line. Patients will be trained how to fill the syringe and put into the vagina. Gel will be administered 2 times per day during the non menstruating day totally for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gel Interferon and interferon suppository arm
Description: 0.2 ml gel interferon will be administered into vaginal using 1 ml syringe with measurement line. Patients will be trained how to fill the syringe and put into the vagina. Gel will be administered 2 times per day during the non menstruating day totally for 28 days.~3MIU suppository will be given to patients and will be trained how to use. Each patient in the arm will use the suppository twice a day for 10 days with vaginal therapy.
Study: NCT05020652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ05105 tablets
Description: TQ05105 tablet is a JAK2 inhibitor, which can be used to treat JAK2 target related diseases, such as moderate or high-risk multiple myelofibrosis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxycarbamide tablets
Description: Hydroxycarbamide tablet is a nucleoside diphosphate reductase inhibitor.
Study: NCT06288776

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Herbal based mouthwash
Description: Herbal based mouthwash will be used to treat the tooth sensitivity in participants having VAS score values of tooth sensitivity ranging between 30-80
Study: NCT05242549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitness and Nutrition Program for Seniors
Description: Fitness and Nutrition Program for Seniors uses the Trans-Theoretical Model (TTM) as the framework, which includes physical activity training, nutrition education- nursing Information, home-based training, and telecare group care (including APP assistance).~Physical activity training comprised muscle training, joint strengthening, and upper and lower limb resistance exercises for older adults who were frail. After administering nutrition education- nursing Information, participants were encouraged to set their own goals to improve their diet. Home-based training and telecare group care depends on the stages of TTM behavior change of the elderly.
Study: NCT05522712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acapella user
Description: The exercise session will include three sets of deep breaths. Each set will include 10 repetitions which were fol¬lowed by 30 to 60 seconds pause in between. Patients will be instructed to perform slow maximal inspiration, while expiration was done through acapella in a prolonged manner to minimize airway closure and alveolar collapse. In the Acapella device, resistance was increased continuously on each successive day. The technique will be applied for 15 minutes.~Components of Acapella® treatment will include :~* Breathing control~* 10 breaths through the Acapella® device~* Inhaling up to approximately three - quarter maximum breathing capacity~* 2-3 second breath hold~* Active exhalation to Functional residual capacity but not too forcefully (3-4 second)~* The patient did 2-3 huffs at the end of the session, Cough or forced expiration in a set cycle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incentive spirometer user
Description: 1. Sit upright in a chair or in bed. Hold the incentive spirometer at eye level, hold a pillow to help splint or brace the incision to decrease pain at incision.~2. Put the mouthpiece in mouth and close lips tightly around it. Slowly breathe out (exhale) completely.~3. Breathe in (inhale) slowly through mouth as deeply as possible. As taking the breath, the ball will rise.~4. Try to get the ball as high as possible.~5. When getting it, hold breath for 10 seconds, or as long as possible.~6. Then, breathe out slowly through mouth. Then, Rest for a 30-60 seconds.~7. Repeat 10 times. Try to get the ball to the same level or higher with each breath.~8. repeat 10 times for 3 sets.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control
Description: This group is a control group will not receive new intervention just traditional chest physiotherapy and mobilization
Study: NCT05092399

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: No study interventions

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: No study interventions
Study: NCT04855565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALY688-SR
Description: single dose subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALY688-SR
Description: single dose subcutaneous injection
Study: NCT05723510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban 60mg
Description: Oral administration of one tablet of edoxaban 60 mg once daily
Study: NCT05896969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNK-396 - SAD cohort
Description: A single dose of SNK-396 within the dose range of 25 to 800 mg, or matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNK-396 - MAD Cohort
Description: Multiple doses of SNK-396 within the dose range of from 25 to 800 mg, or matching placebo.
Study: NCT05683210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cup feeding
Description: The preterm infant was put on pulse oximetry and monitored, and heart rate and oxygen saturation began to be monitored. The infants' heart rate and oxygen saturation were recorded 30 minutes before feeding, and their signs of preparedness for oral feeding were monitored. After the data were recorded for 30 minutes, the infant was taken out of the incubator and his/her body weight was measured naked with only a clean diaper to determine the test weight. Feeding time was limited to 30 minutes, including the infants' resting time. When the infant was no longer sucking, the stopwatch was stopped, and the feeding phase was terminated. The feeding process was completed at the end of 30 minutes even if the infant did not take all of the food. The infant was followed up for 30 minutes after the end of feeding. During this time, the pulse oximetry continued to record and no intervention was made in order to avoid any effect on physiological values.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bottle feeding
Description: The preterm infant was put on pulse oximetry and monitored, and heart rate and oxygen saturation began to be monitored. The infants' heart rate and oxygen saturation were recorded 30 minutes before feeding, and their signs of preparedness for oral feeding were monitored. After the data were recorded for 30 minutes, the infant was taken out of the incubator and his/her body weight was measured naked with only a clean diaper to determine the test weight. During the feeding period, heart rate and oxygen saturation were continuously recorded. Feeding time was limited to 30 minutes, including the infants' resting time. When the infant was no longer sucking, the stopwatch was stopped, and the feeding phase was terminated. The infant was followed up for 30 minutes after the end of the feeding. During this time, the pulse oximetry continued to record and no intervention was made in order to avoid any effect on physiological values.
Study: NCT05723510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban 60mg
Description: Oral administration of one tablet of edoxaban 60 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 5mg
Description: Oral administration of one tablet of apixaban 5 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 5mg
Description: Oral administration of one tablet of apixaban 5 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20mg
Description: Oral administration of one tablet of rivaroxaban 20 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20mg
Description: Oral administration of one tablet of rivaroxaban 20 mg once daily
Study: NCT04467788

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computer-aided sessions
Description: Changing participants' KAP of ergonomics in dentistry

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical simulation sessions
Description: Changing participants' KAP of ergonomics in dentistry
Study: NCT04747756

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Village
Description: The purpose of this study is to create a virtual village for people aging with HIV, and to pilot test the virtual village intervention as a final step.
Study: NCT05262478

Intervention type: DEVICE
Intervention: Alpha-D CDP
Description: Alpha-D cervical disc prosthesis was developed jointly by the Spine Center of Koç University Faculty of Medicine and Toledo University Bioengineering Department. It was designed as a single unit to ensure user-friendly administration for surgeons, and it was designed and manufactured to reproduce the movements of the normal cervical movement segment.
Study: NCT06170450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyclic SNM
Description: SNM cycling: 8 hours on, 16 hours off

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous SNM
Description: Continuous SNM: on continuously, no 'off' period
Study: NCT06265636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous nerve stimulation
Description: Percutaneous nerve stimulation (PENS) involves inserting a dry needling needle through muscle tissue until it reaches a nerve branch. At this point, a bipolar TENS current with different parameters is applied to the needle with the goal of improving the patient's pain perception.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Digital pressure techniques in muscle areas with the aim of reducing the perception of stiffness and pain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Digital pressure techniques in muscle areas with the aim of reducing the perception of stiffness and pain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Exercises for improving mandibular mobility, occlusion coordination and regulation of temporomandibular muscle tone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Exercises for improving mandibular mobility, occlusion coordination and regulation of temporomandibular muscle tone
Study: NCT06491888

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Detection of Cervical Lesions by Fluorescence Photoelectric Image
Description: Photoelectric detection was carried out on the subjects of the experimental group.
Study: NCT06554093

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device - PKS
Description: The PKS spine navigation system is for spatial positioning and orientation of surgical instruments during pedicle screw instrumentation in patients undergoing posterior fusion in single or multiple levels.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device - PKS
Description: The PKS spine navigation system is for spatial positioning and orientation of surgical instruments during pedicle screw instrumentation in patients undergoing posterior fusion in single or multiple levels.
Study: NCT04558112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-DOPA
Description: two gel capsules with 100mg L-DOPA (with 25 mg carbidopa to inhibit peripheral decarboxylase)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two gel capsules of placebo
Study: NCT04795544

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracuff pressure measurement
Description: Intracuff pressure is measured by a pressure manometer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracuff pressure measurement
Description: Intracuff pressure is measured by a pressure manometer.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intracuff pressure measurement
Description: Intracuff pressure is measured by a pressure manometer.
Study: NCT04807725

Intervention type: GENETIC
Intervention: Analysis of genetic polymorphisms
Description: For the investigation of genetic polymorphisms, it will be collected a sample of cells from the jugal mucosa with the aid of a swab. The genetic analysis will be done with the DNA extraction technique followed by PCR-RFLP techniques (polymerase chain reaction followed by restriction fragment length polymorphism).

Intervention type: GENETIC
Intervention: Analysis of genetic polymorphisms
Description: For the investigation of genetic polymorphisms, it will be collected a sample of cells from the jugal mucosa with the aid of a swab. The genetic analysis will be done with the DNA extraction technique followed by PCR-RFLP techniques (polymerase chain reaction followed by restriction fragment length polymorphism).

Intervention type: OTHER
Intervention: Biochemical analysis
Description: For the biochemical analysis of the inflammatory mediators IL-1beta, TNF-alpha and PGE2 a peri-implant crevicular fluid collection will be performed by inserting paper strips into peri-implant sulcus or pocket, in situations of peri-implantitis from the most affected location, while in situations of peri-implant health from the mesio-buccal location.

Intervention type: OTHER
Intervention: Biochemical analysis
Description: For the biochemical analysis of the inflammatory mediators IL-1beta, TNF-alpha and PGE2 a peri-implant crevicular fluid collection will be performed by inserting paper strips into peri-implant sulcus or pocket, in situations of peri-implantitis from the most affected location, while in situations of peri-implant health from the mesio-buccal location.
Study: NCT05095246

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB407 (Nebulization)
Description: Nebulized solution of KB407, a replication-incompetent HSV-1 expressing full length human CFTR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB407 (Nebulization)
Description: Nebulized solution of KB407, a replication-incompetent HSV-1 expressing full length human CFTR
Study: NCT04699903

Intervention type: DIAGNOSTIC_TEST
Intervention: POC SARS-Cov-2 IgG Antibody test
Description: All patients will undergo a Point of care (POC) SARS-Cov-2 IgG Antibody test in fingerstick whole blood

Intervention type: DIAGNOSTIC_TEST
Intervention: POC SARS-Cov-2 IgG Antibody test
Description: All patients will undergo a Point of care (POC) SARS-Cov-2 IgG Antibody test in fingerstick whole blood
Study: NCT04868006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: End-range Maitland mobilization + proprioception training
Description: End-range Maitland mobilization performed in end position of internal rotation of the shoulder accompanied with 8--week long proprioception training

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non end-range Maitland mobilization + proprioception training
Description: Non end-range Maitland mobilization performed in loose position of the shoulder accompanied with 8--week long proprioception training

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham manual therapy technique + proprioception training
Description: Placebo performed in loose position of the shoulder accompanied with 8--week long proprioception training
Study: NCT05095246

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB407 (Nebulization)
Description: Nebulized solution of KB407, a replication-incompetent HSV-1 expressing full length human CFTR
Study: NCT05686616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin Propanediol Hydrate 12.3 mg
Description: Forxiga 10mg will be added on the conventional treatment for SGL2 inhibitor group.
Study: NCT04983329

Intervention type: OTHER
Group type: OTHER
Intervention: Telemedicine intervention
Description: Following education, the telemedicine center will subsequently monitor operating rooms included in this trial for protocol adherence for three-months. The telemedicine center is staffed by attending anesthesiologists, resident anesthesiologists, certified registered nurse anesthetists (CRNAs) and student registered nurse anesthetists (SRNAs) and is currently providing evidence-based support to clinicians in a subset of operating rooms and post-anesthesia care unit (PACU) beds at Barnes-Jewish Hospital.
Study: NCT05137509

Intervention type: DEVICE
Intervention: Computerized Tomography
Description: Using Computerized Tomography for diagnosis COVID -19 patients

Intervention type: DEVICE
Intervention: Computerized Tomography
Description: Using Computerized Tomography for diagnosis COVID -19 patients
Study: NCT05195281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fine Needle Biopsy or Aspiration
Description: A new sampling of the tumor will be performed after 4-6 months of neoadjuvant chemotherapy
Study: NCT05170984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CACIPLIQ20®
Description: Application of CACIPLIQ20® by spray, directly on the wound surface, after wound cleaning and debridement, twice a week, until wound closure (or up to 20 weeks maximum).
Study: NCT06220669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3541860
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3541860
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3541860
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3541860
Description: Administered IV
Study: NCT05140005

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: GlowTest COVID-19 Antigen Home Test
Description: diagnostic testing for Covid 19

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: GlowTest COVID-19 Antigen Home Test
Description: diagnostic testing for Covid 19
Study: NCT06220669

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT01369316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circumferential Submucosal Incision Resection
Description: The patient is randomized, if in the active arm the procedure will continue as Circumferential Submucosal Incision Endoscopic Mucosal Resection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Mucosal Resection
Description: Patients randomised into this Intervention type will have Endoscopic Mucosal Resection performed